|Bid||0.00 x 800|
|Ask||0.00 x 1000|
|Day's Range||195.09 - 199.61|
|52 Week Range||129.21 - 218.00|
|Beta (5Y Monthly)||0.25|
|PE Ratio (TTM)||29.27|
|Earnings Date||Aug 03, 2021|
|Forward Dividend & Yield||3.40 (1.73%)|
|Ex-Dividend Date||May 13, 2021|
|1y Target Est||213.41|
Innovent Biologics, Inc. (HKEX: 01801) and Eli Lilly and Company (NYSE: LLY) today jointly announced that the U.S. Food and Drug Administration (FDA) accepted for review a Biologics License Application (BLA) for sintilimab injection in combination with pemetrexed and platinum chemotherapy for the first-line treatment of people with nonsquamous non-small cell lung cancer (NSCLC). This is the first U.S. regulatory submission of sintilimab, a PD-1 inhibitor being developed and commercialized under a global collaboration agreement between Innovent and Lilly.
Insiders load up on Corteva, Energy Transfer, Elanco Animal Health and CenterPoint Energy
AbCellera stock tumbled Friday, despite in-line royalties for its Lilly-partnered Covid drug. Here's why the stock toppled.